Customer conversations are no longer just automated — they’re adaptive, persistent, and agent-driven.

In 2026, the question won’t be if you use AI agents, but how you operate them safely at scale.

This guide outlines the six predictions driving the shift to agentic CX — and how leading enterprises are preparing their teams, systems, and operations for what’s next.

Get the Guide

⚖ Editor's Note: Standard Wefunder Wednesday disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to invest. Invst Guru is not affiliated with Heal Rapidly, Wefunder, or any broker-dealer. Please review the company's official Reg CF filing and offering documents before investing.

Heal Rapidly is a pharmaceutical startup developing a patent-pending liquid spray that accelerates wound healing by 11-13% while providing a non-toxic, moisture-optimized recovery environment.

The global wound care market is a multi-billion-dollar industry, characterized by traditional adhesive bandages and topical ointments, with limited innovation in recent years. Heal Rapidly is entering this space with a patent-pending liquid bandage spray that provides a more efficient, non-toxic alternative for treating cuts, burns, and infections. By creating a moisture-optimal environment, the company’s formula aims to significantly reduce healing time while simultaneously addressing pain and inflammation.

Founded by a team of veteran scientists and medical professionals, Heal Rapidly seeks to bridge the gap between over-the-counter convenience and clinical-grade efficacy. The company’s focus on objective laboratory data and human safety trials positions it as a science-forward competitor in the pharmaceutical startup landscape. As they approach a target market launch within the next six months, the company is leveraging Regulation Crowdfunding to fund its transition from the R&D phase to commercial distribution and FDA compliance.

Here are 10 things to know about Heal Rapidly's live Reg CF raise:

01 Patent-Pending Formula

The company has developed a proprietary liquid spray that forms a protective barrier, accelerating the natural healing process by an estimated 11-13%.

02 Clinical Trial Data

Lab tests demonstrated a 64.9% increase in burn closure by day four, backed by GLP rabbit studies and human skin irritation trials involving 172 subjects.

03 Expert Leadership Team

The management team includes Thomas Konowalchuk, an MD/JD with 27 pharmaceutical patents, and a world-renowned virologist.

04 Pending FDA Approval

A primary risk and milestone is the pending FDA 510(k) clearance required to market the product as a regulated liquid wound dressing.

05 Rapid Go-To-Market Strategy

Upon achieving regulatory approval, the company intends to launch the product within six months, targeting both consumer and professional medical segments.

06 Convertible Note Terms

The current investment round is structured as a Convertible Note with a $3.5 million valuation cap and a 10% annual interest rate.

07 Funding and Tractions

Heal Rapidly has already secured over $152,000 from 167 individual investors toward its $350,000 funding goal.

08 Competitive Landscape

The company faces significant competition from established household wound care brands and emerging stabilized hypochlorous acid solutions.

09 Financial Projections

Management projects $2.4 million in sales within the first two years post-launch, though these figures are hypothetical and contingent on market adoption.

10 Concentration Risk

The company’s current value is heavily reliant on a single product line, making successful regulatory approval and therapeutic claim expansion critical.

Heal Rapidly represents a science-driven approach to the traditional wound care market, led by an experienced medical and legal team. While initial studies support the potential for accelerated healing, the company's success depends on navigating the FDA approval process and capturing market share from legacy brands. Investors should carefully review the offering details and the Form C filing on the Wefunder platform to understand the risks and terms involved.

👉 View the live campaign on Wefunder: Heal Rapidly Campaign

⚖️ Disclaimer:

Invst Guru: Wefunder Wednesday is a third-party editorial feature created by Invst Guru. We are not affiliated with Wefunder, any Reg CF campaign featured, or any broker-dealer. This content is for informational purposes only and does not constitute investment advice or a solicitation to invest.

If any company mentioned is currently conducting a Regulation Crowdfunding (Reg CF) offering, all investments must be made through a registered funding portal or broker-dealer. No investment terms (such as price, valuation, or offering deadlines) are included in this publication. For full offering details, including disclosures and risk factors, please visit the company's official campaign page on the Wefunder platform.

Investing in early-stage companies involves substantial risk, including the potential loss of your entire investment. Always do your own due diligence and consult a licensed financial advisor before making investment decisions.

Source: https://wefunder.com/heal.rapidly